CDK8 and ovarian cancer: 69–72 In contrast, SNX631 effectively abrogated the development of anoikis resistance in various ovarian cancer models at a concentration (500 nM) that had little or no effect on ovarian cancer cell growth but was sufficient for nearly complete inhibition of CDK8/19 kinase activity.